Payment overview · 2025
General Payments
$18,644.71
45 reported records · 14 companies
Healthcare provider profile · identity verified
Donald A Barone, DO
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · CAMDEN, NJ · NPI 1396933768
Verified facts
What the public records show
CMS Open Payments records show Donald A Barone, DO received $18,644.71 in general payments during 2025 across 45 reported records.
EMD Serono, Inc. accounted for 60.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Tysabri, Vumerity.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TYSABRI as an associated drug or biological on 12612 records involving 3572 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Tysabri by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VUMERITY as an associated drug or biological on 16193 records involving 4044 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vumerity by this doctor in 2024.
Merz Pharmaceuticals, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AMPYRA as an associated drug or biological on 1518 records involving 947 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ampyra by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $11,269.16 | 60.4% | 10 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $6,311.76 | 33.9% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $281.94 | 1.5% | 10 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $126.98 | 0.7% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $124.99 | 0.7% | 1 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $124.99 | 0.7% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $119.70 | 0.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $83.06 | 0.5% | 5 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $49.47 | 0.3% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $42.69 | 0.2% | 2 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $41.74 | 0.2% | 2 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $34.72 | 0.2% | 2 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $17.81 | 0.1% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $15.70 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $15,083.00 | 3 |
| Travel and Lodging | $2,098.73 | 2 |
| Food and Beverage | $1,336.00 | 38 |
| Education | $126.98 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Mavenclad Normalized: mavenclad |
Drug | EMD Serono, Inc. | $10,695.00 | 2 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $6,311.76 | 4 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $261.31 | 9 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation, E.R. Squibb & Sons, L.L.C. | $142.80 | 2 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $126.98 | 2 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $83.06 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $46.53 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $42.69 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $42.69 | 2 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $41.74 | 2 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $41.74 | 2 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $34.72 | 2 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $34.72 | 2 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $34.45 | 2 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $17.61 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $15.70 | 1 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $15.02 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TYSABRI tysabri |
2025 | Tysabri | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VUMERITY vumerity |
2025 | Vumerity | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | TYSABRI open payments reported associated product |
CMS Open Payments — General Payments 12612 supporting records · 3572 recipient NPIs · example record 1208299693 |
Tysabri · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | VUMERITY open payments reported associated product |
CMS Open Payments — General Payments 16193 supporting records · 4044 recipient NPIs · example record 1208299697 |
Vumerity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Merz Pharmaceuticals, LLC Exact reporting entity; no affiliate inference |
2025 | AMPYRA open payments reported associated product |
CMS Open Payments — General Payments 1518 supporting records · 947 recipient NPIs · example record 1232555387 |
Ampyra · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 357 | 82 |
| Baclofen | Baclofen | 180 | 48 |
| Copaxone | Glatiramer Acetate | 130 | 16 |
| Dalfampridine Er | Dalfampridine | 122 | 19 |
| Teriflunomide | Teriflunomide | 107 | 17 |
| Pregabalin | Pregabalin | 87 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 77 | 19 |
| Glatiramer Acetate | Glatiramer Acetate | 75 | 11 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 66 | 12 |
| Carbamazepine Er | Carbamazepine | 58 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 57 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 14 |
| Diazepam | Diazepam | 49 | 12 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 48 | 15 |
| Propranolol Hcl Er | Propranolol Hcl | 46 | suppressed |
| Levetiracetam | Levetiracetam | 40 | suppressed |
| Fingolimod | Fingolimod Hcl | 39 | suppressed |
| Modafinil | Modafinil | 37 | suppressed |
| Clonazepam | Clonazepam | 35 | suppressed |
| Topiramate | Topiramate | 35 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Alprazolam | Alprazolam | 31 | suppressed |
| Aubagio | Teriflunomide | 31 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 31 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 29 | suppressed |
| Prednisone | Prednisone | 26 | suppressed |
| Lamotrigine | Lamotrigine | 25 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Avonex (4 Pack) | Interferon Beta-1a | 19 | suppressed |
| Glatopa | Glatiramer Acetate | 19 | suppressed |
| Octagam | Immun Globg(Igg)/Malt/Iga Ov50 | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Amantadine | Amantadine Hcl | 17 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Gilenya | Fingolimod Hcl | 14 | suppressed |
| Vumerity | Diroximel Fumarate | 14 | suppressed |
| Ampyra | Dalfampridine | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Rebif Rebidose | Interferon Beta-1a/Albumin | 13 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Tysabri | Natalizumab | 12 | suppressed |
| Armodafinil | Armodafinil | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Kesimpta Pen | Ofatumumab | 11 | suppressed |
| Tetrabenazine | Tetrabenazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $18,644.71 · 45 records | EMD Serono, Inc. | BOTOX, BRIUMVI, INGREZZA, Mavenclad, NURTEC ODT, PONVORY, QULIPTA, Rystiggo, TYSABRI, UBRELVY, UPLIZNA, VUMERITY, VYVGART, VYVGART HYTRULO, Xeomin, ZAVZPRET, ZEPOSIA, Zilbrysq | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Tysabri play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Biogen, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error